Previous 10 | Next 10 |
Compugen (NASDAQ: CGEN ) has priced its public offering of ~8.3M ordinary shares at $9.00 per share, for expected gross proceeds of ~$75M. More news on: Compugen Ltd., Healthcare stocks news, , Read more ...
HOLON, Israel , March 12, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the pricing of an underwritten public offering of 8,333,334 ordinary shares at a price to the public of...
Gainers: GOGO +8.4% . SIEN +6.6% . GLNG +6.5% . NVAX +6.4% . INXN +5.8% . More news on: Gogo Inc., Sientra, Inc., Golar LNG Limited, Stocks on the move, , , News on ETFs Read more ...
HOLON, Israel , March 11, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to is...
Shares of Compugen (NASDAQ: CGEN) are up 20% at 2:24 p.m. EDT Tuesday after the company released encouraging data from an early-stage clinical trial testing its cancer treatment COM701. Compugen had previously reported that nine of the first 13 patients treated in the clinical trial had sta...
Gainers: Safe-T Group (NASDAQ: SFET ) +58% . More news on: Safe-T Group Ltd, Enable Midstream Partners, LP, Cypress Semiconductor Corporation, Stocks on the move, , Read more ...
HOLON, Israel , March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ongoing Phase 1 dose escalation study of COM701 in patients with advanced solid ...
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q4 2019 Earnings Call Feb 20, 2020 , 8:30 a.m. ET Operator Continue reading
Compugen Ltd. (CGEN) Q4 2019 Earnings Conference Call February 20, 2020 8:30 A.M. ET Company Participants Elana Holzman - Director of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Henry Adewoye - Chief Medical Officer A...
Compugen (NASDAQ: CGEN ) plans to initiate a Phase 1/2 clinical trial evaluating COM701, combined with Bristol-Myers Squibb's (NYSE: BMY ) Opdivo (nivolumab) and BMS-986207, in patients with solid tumors (including ovarian and endometrial cancers). The primary objective is to assess the sa...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...